HomeIndiaExsure Raises Rs 3 Cr in Seed Funding

Exsure Raises Rs 3 Cr in Seed Funding

-

Exsure

Exsure, a Bhubaneswar, India-based biotech startup reducing side-effects and toxicity of anti-cancer drugs, raised Rs 3 Cr in a Seed Funding.

The round was led by Unicorn India Ventures.

Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is a biotech startup working to reduce side-effects and toxicity of anti-cancer drugs by its patented exosomal drug-delivery platform that targets both cancer and cancer-stem cells. With its technology the company aims at reducing the toxic effects of chemotherapy and chances of cancer relapse improving the quality of lives of patients suffering from cancer. In the last 12 months, Exsure has initiated the non-clinical study in India in collaboration with a CRO and completed one of its milestones in the preclinical study using its patented technology. The company is on track to service more than 50 clients this year with its R&D products, Exosure (3-in-1 exosome isolation reagent),  Leucosure (PBMC isolation reagent) and PlantExosure (India’s 1st Plant exosome isolation reagent). In the coming 12 months, Exsure will finish the non-clinical study and work on team building. The company also plans to present its data for CDSCO approval, strengthen the team size along with expanding its product marketing and sales at a global level.

The company intends to use the funds to complete non-clinical study with its Exosome-based drug delivery vehicle, expand globally its in-house manufactured R&D products, and promote Exosure, Leucosure, PlantExosure and Dr Berries.

It has also been selected for the OIST Innovation Accelerator program in Japan for business expansion and conducting clinical trials.

FinSMEs

22/01/2025

THE DAILY NEWSLETTER - SIGNUP